CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Ipswich Investment Management Co. Inc.

Ipswich Investment Management Co. Inc. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,288 shares of the company’s stock after buying an additional 750 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in CRISPR Therapeutics were worth $995,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CRSP. Blue Trust Inc. increased its position in shares of CRISPR Therapeutics by 158.7% during the third quarter. Blue Trust Inc. now owns 3,844 shares of the company’s stock worth $181,000 after purchasing an additional 2,358 shares in the last quarter. Eastern Bank acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $70,000. International Assets Investment Management LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $1,825,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of CRISPR Therapeutics by 15.9% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 40,568 shares of the company’s stock worth $1,906,000 after buying an additional 5,567 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in CRISPR Therapeutics by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock worth $146,000 after acquiring an additional 545 shares during the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Down 5.0 %

CRISPR Therapeutics stock opened at $47.91 on Friday. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $91.10. The firm has a market cap of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. The company’s 50 day moving average is $42.25 and its two-hundred day moving average is $46.06.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a research report on Wednesday, February 12th. Barclays boosted their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group dropped their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.